|
|
|
|
Clinical trials are conducted in research
settings, designed to answer specific
questions about biomedical or behavioural
interventions, including new treatments
– such as novel vaccines, drugs, dietary
choices and supplements and medical
devices – as well as known interventions
that warrant further study and comparison.
They generate critical data on safety and
efficacy, which is then submitted to the
regulatory authorities responsible for
vetting the risk versus benefit ratio
of the trial.
As the demand for new therapies and
treatments persists, the need for clinical
studies expands globally. This comes
with a growing need for organisations
to ensure they are able to design, start up
and execute their trials, thus delivering
critical information regarding the results. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Datwyler Launches 5/8-Inch Rigid Needle Shield, Infusion Discs
Altdorf, Switzerland, 11 July 2022— Datwyler, a leading
manufacturer of elastomer components for pharmaceutical packaging, is
expanding its portfolio with two new products to meet evolving patient
demands. The new offerings include a 5/8 in. rigid needle shield (RNS)
to address the rising need for prefilled syringes to contain vaccines
for intramuscular injection, and isoprene rubber discs for infusion
therapies.
More info >> |
|
 |
White Papers |
 |
|
Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling
Sartorius Group
The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >> |
|
|
